Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients

NCT07709013 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancies

Interventions

DRUG: Leflunomide 20 mg

Sponsor

Tata Memorial Centre

Collaborators

[object Object]